Aβ clearance represents a novel therapeutic agent with significant potential, as evidenced by Donanemab's substantial reduction of the plasma biomarkers PTAU217 and neurofilament light chain over a 72-week treatment period, indicating its potential impact on AD pathology. This evidence concerns the gene NEFL and Alzheimer disease.